135
Participants
Start Date
December 31, 2009
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Perifosine
Perifosine will be dosed as one 50 mg pill every day of each cycle.
Perifosine Placebo
Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
Bortezomib
Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
Dexamethasone
Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
Great Neck
Prague
Afula
Columbia
Baltimore
Nahariya
Roanoke
Christiansburg
Salem
Madrid
Madrid
Madrid
Madrid
Pamplona
Haifa
Kingsport
San Cristóbal de La Laguna
Valencia
Petah Tikva
Zaragoza
Tel Litwinsky
Milwaukee
Fargo
Winfield
Niles
Brno
Tel Aviv
Dallas
Tyler
Bedford
Rehovot
Fort Worth
Kerrville
San Antonio
San Antonio
Ashkelon
Aurora
Littleton
Parker
Denver
Lakewood
Thornton
Boulder
Longmont
Colorado Springs
Pueblo
Beersheba
Ogden
Jerusalem
Jerusalem
La Verne
San Francisco
San Pablo
Tualatin
Portland
Seattle
Vancouver
Spokane
Moscow
Moscow
Saint Petersburg
Saint Petersburg
Samara
Dana Farber Cancer Institute, Boston
Morristown
Winnipeg
Montreal
Montreal
Québec
Keryx / AOI Pharmaceuticals Investigative Site, Dublin
Dublin
Galway
Limerick
Sligo
Tullamore
Waterford
Košice
Seoul
Seoul
Seoul
Seoul
Seoul
Badalona
Barcelona
Barcelona
Barcelona
Lead Sponsor
Dana-Farber Cancer Institute
OTHER
AEterna Zentaris
INDUSTRY